The partnership for influenza vaccine introduction (PIVI): Supporting influenza vaccine program development in low and middle-income countries through public-private partnerships
Închide
Conţinutul numărului revistei
Articolul precedent
Articolul urmator
841 0
SM ISO690:2012
BRESEE, Joseph S., FURTUNA, Nicolae, CAPMARI, Dumitru. The partnership for influenza vaccine introduction (PIVI): Supporting influenza vaccine program development in low and middle-income countries through public-private partnerships. In: Vaccine, 2019, nr. 35(37), pp. 5089-5095. ISSN -. DOI: https://doi.org/10.1016/j.vaccine.2019.06.049
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
Vaccine
Numărul 35(37) / 2019 / ISSN - /ISSNe 0264-410X

The partnership for influenza vaccine introduction (PIVI): Supporting influenza vaccine program development in low and middle-income countries through public-private partnerships

DOI:https://doi.org/10.1016/j.vaccine.2019.06.049

Pag. 5089-5095

Bresee Joseph S.1, Furtuna Nicolae2, Capmari Dumitru2
 
1 Center for Disease Control and Prevention, Atlanta,
2 Ministerul Sănătăţii al Republicii Moldova
 
 
Disponibil în IBN: 14 august 2019


Rezumat

Influenza vaccination remains the most effective tool for reducing seasonal influenza disease burden. Few Low and Middle-Income Countries (LMICs) have robust, sustainable annual influenza national vaccination programs. The Partnership for Influenza Vaccine Introduction (PIVI) was developed as a public-private partnership to support LMICs to develop and sustain national vaccination programs through time-limited vaccine donations and technical support. We review the first 5 years of experience with PIVI, including the concept, country progress toward sustainability, and lesson learned. Between 2013 and 2018, PIVI worked with Ministries of Health in 17 countries. Eight countries have received donated vaccines and technical support; of these, two have transitioned to sustained national support of influenza vaccination and six are increasing national support of the vaccine programs towards full transition to local vaccine program support by 2023. Nine additional countries have received technical support for building the evidence base for national policy development and/or program evaluation. PIVI has resulted in increased use of vaccines in partner countries, and early countries have demonstrated progress towards sustainability, suggesting that a model of vaccine and technical support can work in LMICs. PIVI expects to add new country partners as current countries transition to self-reliance.